The Advisory Committee on Immunization Practices (ACIP) has voted 5-2 to recommend Merck & Co.'s Enflonsia, a new respiratory syncytial virus (RSV) antibody, for use in infants born during or entering their first RSV season. This endorsement marks a significant advancement in infant RSV prophylaxis, expanding options for protecting vulnerable populations during RSV outbreaks. The recommendation reflects the latest assessment of efficacy and safety data supporting Enflonsia's use in this age group, with potential implications for pediatric infectious disease prevention strategies.